Dose intensity in advanced ovarian cancer: have we answered the question? - Suppr | 超能文献

Dose intensity in advanced ovarian cancer: have we answered the question?

作者信息

Fennelly D

机构信息

Breast and Gynecological Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

出版信息

Clin Cancer Res. 1995 Jun;1(6):575-82.

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Dose intensity in advanced ovarian cancer: have we answered the question?

Clin Cancer Res. 1995 Jun;1(6):575-82.

2

Role of carboplatin in ovarian cancer. Current results and thoughts for the future.

Acta Obstet Gynecol Scand Suppl. 1992;155:75-7.

3

[Carboplatin in cancer of the ovary].[卡铂用于卵巢癌治疗]

Bull Cancer. 2000 Aug;87 Spec No:40-7.

4

Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.铂类新辅助化疗用于晚期卵巢癌

Gynecol Oncol. 2007 Jul;106(1):273-4; author reply 274-5. doi: 10.1016/j.ygyno.2007.03.013. Epub 2007 Apr 30.

5

[First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].

Bull Cancer. 2000 Feb;87(2):189-99.

6

[Dose intensity in chemotherapy of ovarian carcinoma: to what degree?].

Clin Ter. 1998 Nov-Dec;149(6):397-9.

7

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.在接受铂类化疗的上皮性卵巢癌患者中，p53（而非p21WAF1/Cip1）蛋白浓度、生存率和反应性之间存在剂量反应效应的证据。

Clin Cancer Res. 2000 Aug;6(8):3260-70.

8

Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.紫杉醇（泰素）/卡铂联合化疗治疗晚期卵巢癌

Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7.

9

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.卵巢癌腹腔内顺铂治疗：与标准静脉注射卡铂和紫杉醇的比较。

Gynecol Oncol. 2006 Oct;103(1):1-6. doi: 10.1016/j.ygyno.2006.06.026. Epub 2006 Aug 10.

10

Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?铂类药物敏感的复发性卵巢癌二线治疗：最佳治疗方案是什么？

Gynecol Oncol. 2001 Apr;81(1):1-2. doi: 10.1006/gyno.2001.6162.

引用本文的文献

1

Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy.使用生物素靶向甲氨蝶呤-人血清白蛋白偶联纳米粒增强甲氨蝶呤的抗肿瘤疗效。

Int J Nanomedicine. 2011;6:1863-74. doi: 10.2147/IJN.S23949. Epub 2011 Sep 8.

2

Chemopreventive effects of Peucedanum praeruptorum DUNN and its major constituents on SGC7901 gastric cancer cells.白花前胡及其主要成分对 SGC7901 胃癌细胞的化学预防作用。

Molecules. 2010 Nov 9;15(11):8060-71. doi: 10.3390/molecules15118060.

3

pHLIP-mediated translocation of membrane-impermeable molecules into cells.pHLIP介导的膜不透性分子向细胞内的转运。

Chem Biol. 2009 Jul 31;16(7):754-62. doi: 10.1016/j.chembiol.2009.06.006.

4

Canine parvovirus-like particles, a novel nanomaterial for tumor targeting.

J Nanobiotechnology. 2006 Feb 13;4:2. doi: 10.1186/1477-3155-4-2.

5

Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.促黄体生成素释放激素（LHRH）肽对抗癌药物递送系统的肿瘤特异性靶向作用。

Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7. doi: 10.1073/pnas.0504274102. Epub 2005 Aug 25.

6

IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.卵巢癌中白细胞介素-6的产生与肿瘤的组织类型和生物学特性相关，并影响局部免疫。

Br J Cancer. 2000 Feb;82(3):621-8. doi: 10.1054/bjoc.1999.0973.